Effects of obesity on treatment response to Janus kinase inhibitors (JAKi) in rheumatoid arthritis

Project Overview
This study aims to investigate how obesity influences the effectiveness of Janus kinase inhibitors (JAKi), a class of immunotherapies used to treat rheumatoid arthritis (RA). By combining data from multiple studies, the research seeks to provide a deeper understanding of how body weight impacts treatment outcomes for these drugs.

Context and background of the study topic
Obesity is a significant and growing global health issue, with rising prevalence and widespread negative effects on health that go beyond metabolic and cardiovascular complications. Among individuals with RA, obesity is even more common, affecting approximately 1 in 4 patients. Rheumatoid arthritis is an autoimmune disease, which means that the immune system (which usually fights infection) attacks the cells that line the joints by making them swollen, stiff and painful. Adipose tissue (body fat) in obese individuals contains elevated levels of pro-inflammatory immune cells, which contribute to the chronic inflammation underlying RA disease activity.

Summary of Existing Research
Emerging evidence indicates that obesity can make it more challenging for patients with RA to reduce inflammation and achieve effective disease control with immunotherapies. However, there is limited research on how obesity specifically impacts the response to Janus kinase inhibitors (JAKi) These immunotherapies target Janus kinase enzymes, which play a central role in the inflammatory pathways driving RA, thereby helping to reduce joint swelling, pain, and tissue damage. JAK inhibitors are being used increasingly in RA treatment, supported by robust evidence of their effectiveness.

Rationale for the Study
Analysing data from all JAKi clinical trials offers a unique opportunity to study a larger and more diverse patient population, including those in severely obese categories. This approach also enables direct comparison with other immunotherapies. Using individual participant data has several benefits over aggregate data, permitting the analysis all important outcomes and using a consistent unit and method of analysis. It is vital for us to understand how obesity interacts with JAKi. Not only will this inform therapeutic decisions in clinical practice, but it may also support the proactive utilisation of novel weight-loss strategies alongside immunotherapy in the ultimate goal of improving outcomes for individuals with RA.